Modern treatment options for intracerebral hemorrhage

Current Treatment Options in Neurology

Volumn 8, Issue 2, 2006, Pages 145-157

  Freeman, William D ^b   Brott, Thomas G ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; AMINOCAPROIC ACID; ANTITHROMBOCYTIC AGENT; BUSPIRONE; CLOPIDOGREL; DEXAMETHASONE; DEXMEDETOMIDINE; ENALAPRILAT; ESMOLOL; FENTANYL; FRESH FROZEN PLASMA; GAVESTINEL; GLYCEROL; INFUSION FLUID; LABETALOL; MANNITOL; NEUROMUSCULAR BLOCKING AGENT; NICARDIPINE; PARACETAMOL; PETHIDINE; PHYTOMENADIONE; PLACEBO; PROPOFOL; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SHORT ACTING DRUG; TICLOPIDINE; VITAMIN K GROUP; WARFARIN;

ANAPHYLAXIS; BRAIN EDEMA; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID DRAINAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEVER; HEART INFARCTION; HEMATOMA; HUMAN; HYDROCEPHALUS; HYPERTENSION; INTRACRANIAL HYPERTENSION; META ANALYSIS; MICROANGIOPATHY; MORTALITY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REVIEW; SEIZURE; SHIVERING; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT FAILURE; VASCULAR AMYLOIDOSIS;

EID: 33344473788     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-006-0005-y     Document Type: Review

References (98)

1. Broderick JP, Brott TG, Tomsick T, et al.: Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg 1993, 78:188-191.
2. Broderick JP, Brott TG, Duldner JE, et al.: Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke 1993, 24:987-993.
3. Brott T, Broderick JP, Kothari R, et al.: Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997, 28:1-5.
4. Broderick JP, Adams HP Jr, Barsan W, et al.: Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999, 30:905-915.
5. Hemphill JC, Bonovich DC, Besmertis L, et al.: The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 2001, 32:891-897.
6. Tuhrim S, Horowitz DR, Sacher M, Godbold JH: Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med 1999, 2:617-621.
7. Huang CH, Wen-Jone C, Chang WT, et al.: QTc dispersion as a prognostic factor in intracerebral hemorrhage. Am J Emerg Med 2004, 22:141-144.
8. Vemmos KN, Tsivgoulis G, Spengos K, et al.: U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004, 255:257-265.
9. Fogelholm R, Murros K, Rissanen A, Avikainen S: Admission blood glucose and short-term survival in primary intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatr 2005, 76:349-353.
10. Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005, 36:1588-1593.
11. Woo D, Sauerbeck LR, Kissela BM, et al.: Genetic and environmental risk factors for intracerebral hemorrhage. Stroke 2002, 33:1190-1196.
12. Fang MC, Chang Y, Hylek EM, et al.: Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745-752.
13. Smith EE, Rosand J, Knudsen KA, et al.: Leukoariosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002, 59:193-197.
14. Jeerakathil T, Wolf PA, Beiser A, et al.: Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004, 35:1831-1835.
15. Nighoghossian N, Hermier M, Adeleine P, et al.: Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study. Stroke 2002, 33:735-742.
16. Lee SH, Bae HJ, Kwon SJ, et al.: Cerebral microbleeds are regionally associated with intracerebral hemorrhage. Neurology 2004, 62:72-76.
17. Greenberg SM, Eng JA, Ning M, et al.: Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004, 35:1415-1420.
18. Roob G, Schmidt E, Kapeller P, et al.: MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 1999, 52:991-994.
19. Qureshi AI, Tuhrim S, Broderick JP, et al.: Spontaneous intracerebral hemorrhage. N Eng J Med 2001, 344:1450-1460.
20. Fisher CM: Pathological observations in hypertensive cerebral hemorrhage. J Neuropath Exp Neurol 1971, 30:536-550.
21. Garcia JH, Ho KL: Pathology of hypertensive cerebral arteriopathy. Neurosurg Clin N Am 1992, 3:497-507.
22. Schellinger PD, Fiebach JB: Intracranial hemorrhage: the role of magnetic resonance imaging. Neurocrit Care 2004, 1:31-46.
23. Kothari RU, Brott T, Broderick JP, et al.: The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996, 27:1304-1305.
24. Zuccarello M, Brott T, Derex L, et al.: Early surgical treatment for supratentorial intracerebral hemorrhage: a randomized feasibility study. Stroke 1999, 30:1833-1839.
25. Yu YL, Kumana CR, Lauder IJ, et al.: Treatment of acute cerebral hemorrhage with intravenous glycerol. A double blind, placebo-controlled, randomized trial. Stroke 1992, 23:967-971.
26. Haley EC, Thompson JLP, Levin B, et al.: Gavestinel does not improve outcome after acute intracerebral hemorrhage. Stroke 2005, 36:1006-1010.
27. Poungvarin N, Bhoopat W, Viriyavejakul A, et al.: Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 1987, 316:1229-1233.
28. Tellez H, Bauer RB: Dexamethasone as treatment in cerebrovascular disease. 1. A controlled study in intracerebral hemorrhage. Stroke 1973, 4:541-546.
29. Piriyawat P, Morgenstern LB, Yawn D, et al.: Treatment of acute intracerebral hemorrhage with epsilon-aminocaproic acid: a pilot study. Neurocrit Care 2004, 1:47-52.
30. Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF: Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc 2005, 80:420-433.
31. Powers WJ, Zazulia AR, Videen TO, et al.: Autoregulation of cerebral blood flow surrounding acute (6 to 22 hours) intracerebral hemorrhage. Neurology 2001, 57:18-24.
32. Toyoda K, Okada Y, Minematsu K, et al.: Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology 2005, 65:1000-1004.
33. Qureshi AI, Bliwise DL, Bliwise NG, et al.: Rate of 24-hour blood pressure decline and mortality after spontaneous intracerebral hemorrhage: a retrospective analysis with a random effects regression model. Crit Care Med 1999, 27:480-485.
34. Qureshi AI, Wilson DA, Hanley DF, Traystman RJ: Pharmacologic reduction of mean arterial pressure does not adversely affect regional cerebral blood flow and intracranial pressure in experimental intracerebral hemorrhage. Crit Care Med 1999, 27:965-971.
35. Qureshi AI, Mohammad YM, Yahia AM, et al.: A prospective multicenter study to evaluate the feasibility and safety of aggressive antihypertensive treatment in patients with acute intracerebral hemorrhage. J Intensive Care Med 2005, 20:34-42.
36. Zazulia AR, Diringer MN, Videen TO, et al.: Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab 2001, 21:804-810.
37. Carhuapoma JR, Gupta K, Coplin WM, et al.: Treatment of refractory fever in the neurosciences critical care unit using a novel, water-circulating cooling device. A single-center pilot experience. J Neurosurg Anesthesiol 2003, 15:313-318.
38. Diringer MN, Neurocritical Care Fever Reduction Trial Group: Treatment of fever in the neurologic intensive care unit with a catheter-based heat exchange system. Crit Care Med 2004, 32:559-564.
39. Leira R, Davalos A, Silva Y, et al.: Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology 2004, 10:461-467.
40. Marion DW: Controlled normothermia in neurologic intensive care. Crit Care Med 2004, 32(Suppl):S43-S45.
41. Ritter AM, Robertson CS: Cerebral metabolism. Neurosurg Clin N Am 1994, 5:633-645.
42. Mayer SA, Kowalski RG, Presciutti M, et al.: Clinical trial of a novel surface cooling system for fever control in neurocritical care patients. Crit Care Med 2004, 32:2508-2515.
43. Doufas AG, Sessler DI: Physiology and clinical relevance of induced hypothermia. Neurocrit Care 2004, 1:489-498.
44. O'Grady NP, Barie PS, Bartlett J, et al.: Practice parameters for evaluating new fever in critically ill adult patients. Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. Crit Care Med 1998, 26:392-408.
45. Frank SM, Fleisher LA, Breslow MJ, et al.: Perioperative maintenance of normothermia reduces the incidence of morbid cardiac events. A randomized clinical trial. JAMA 1997, 277:1127-1134.
46. Doufas AG, Lin CM, Suleman MI, et al.: Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke 2003, 34:1218-1223.
47. Mokhtarani M, Mahgoub AN, Morioka N, et al.: Buspirone and meperidine synergistically reduce the shivering threshold. Anesth Analg 2001, 93:1233-1239.
48. Fujii Y, Tanaka R, Takeuchi S, et al.: Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg 1994, 80:51-57.
49. Kazui S, Minematsu K, Yamamoto H, et al.: Predisposing factors to enlargement of spontaneous intracerebral hemorrhage. Stroke 1997, 28:2370-2375.
50. Ohwaki K, Yano E, Nagashima H, et al.: Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004, 35:1364-1367.
51. Mayer SA, Brun NC, Begtrup K, et al.: Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-785.
52. NovoSeven. Package Insert. Princeton, NJ: Novo Nordisk; 2005.
53. Erhardtsen E: Ongoing NovoSeven trials. Intensive Care Med 2002, 28(Suppl 2):S248-S256.
54. Freeman WD, Brott TG, Barrett KM, et al.: Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004, 79:1495-1500.
55. Fewel ME, Park P: The emerging role of recombinant-activated factor VII in neurocritical care. Neurocrit Care 2004, 1:19-30.
56. Hart RG: What causes intracerebral hemorrhage during warfarin therapy? Neurology 2000, 55:907-908.
57. Franke CL, de Jonge J, van Swieten JC, et al.: Intracerebral hemorrhage during anticoagulation treatment. Stroke 1990, 21:726-730.
58. Rosand J, Eckman MH, Knudsen KA, et al.: The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004, 164:880-884.
59. Sjoblom L, Hardemark HG, Lindgren A, et al.: Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001, 32:2567-2574.
60. Neau JP, Couderq C, Ingrand P, et al.: Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis 2001, 11:195-200.
61. Yasaka M, Minematsu K, Naritomi H, et al.: Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003, 89:278-283.
62. Brody DL, Aiyagari V, Shackleford AM, Diringer MN: Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005, 2:263-267.
63. Park P, Fewel ME, Garton HJ, et al.: Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophiliac neurosurgical patients. Neurosurgery 2003, 53:34-38.
64. Lin J, Hanigan WC, Tarantino M, Wang J: The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 2003, 98:737-740.
65. Deveras RA, Kessler CM: Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002, 137:884-888.
66. Sorenson B, Johansen P, Nielson GL, et al.: Reversal of International Normalized Ratio with recombinant factor VIIa in central nervous system bleeding during warfarin thrombophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis 2003, 14:469-477.
67. Hirsh J, Fuster V, Ansell J, et al.: American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003, 41:1633-1652.
68. AquaMEPHYTON. In Physician's Desk Reference. Montvale, NJ: Medical Economics Company, Inc.; 2001.
69. Riegert-Johnson DL, Volcheck GW: The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002, 89:400-406.
70. Fiore LD, Scola MA, Cantillon CE, Brophy MT: Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001, 11:175-183.
71. Olson JD: Mechanisms of hemostasis. Effect on intracerebral hemorrhage. Stroke 1993, 24(Suppl):I109-I114.
72. Schulman S: Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675-683.
73. Akdemir H, Selcuklu A, Pasaoglu A, et al.: Treatment of severe intraventricular hemorrhage by intraventricular infusion of urokinase. Neurosurg Rev 1995, 18:95-100.
74. Coplin WM, Vinas FC, Agris JM, et al.: A cohort study of the safety and feasibility of intraventricular urokinase for nonaneurysmal spontaneous intraventricular hemorrhage. Stroke 1998, 29:1573-1579.
75. Naff NJ, Carhuapoma JR, Williams MA, et al.: Treatment of intraventricular hemorrhage with urokinase: effects on 30-day survival. Stroke 2000, 31:841-847.
76. Tung MY, Ong PL, Seow WT, Tan KK: A study on the efficacy of intraventricular urokinase in the treatment of intraventricular haemorrhage. Br J Neurosurg 1998, 12:234-239.
77. Naff NJ, Hanley DF, Keyl PM, et al.: Intraventricular thrombolysis speeds blood dot resolution: results of a pilot, prospective, randomized double-blind, controlled trial. Neurosurgery 2004, 54:577-583.
78. Engelhard HH, Andrews CO, Slavin KV, Charbel FT: Current management of intraventricular hemorrhage. Surg Neurol 2003, 60:15-22.
79. Hanley DF, Hacke W: Critical care and emergency medicine neurology in stroke. Stroke 2005, 36:205-207.
80. Xi G, Keep RF, Hoff JT: Pathophysiology of brain edema formation. Neurosurg Clin N Am 2002, 13:371-383.
81. Gebel JM, Jauch EC, Brott TG, et al.: Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002, 33:2636-2641.
82. Gebel JM, Jauch EC, Brott TG, et al.: Natural history of perihematomal edema in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke 2002, 33:2631-2635.
83. Xi G, Wagner KR, Keep RF, et al.: Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke 1998, 29:2580-2586.
84. Gebel JM, Brott TG, Sila CA, et al.: Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage. Stroke 2000, 31:596-600.
85. Wagner KR, Xi G, Hua Y, et al.: Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection. J Neurosurg 1999, 90:491-498.
86. Rincon F, Mayer SA: Novel therapies for intracerebral hemorrhage. Curr Opin Crit Care 2004, 10:94-100.
87. Cruz J, Minoja G, Okuchi K: Major clinical and physiological benefits of early high doses of mannitol for intraparenchymal temporal lobe hemorrhages with abnormal pupillary widening: a randomized trial. Neurosurgery 2002, 51:628-637.
88. Larive LL, Rhoney DH, Parker D Jr, et al.: Introducing hypertonic saline for cerebral edema: an academic center experience. Neurocrit Care 2004, 1:435-440.
89. Qureshi AI, Wilson DA, Traystman RJ: Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol and hypertonic saline. Neurosurgery 1999, 44:1055-1063.
90. Ogden AT, Mayer SA, Connolly ES Jr: Hyperosmolar agents in neurosurgical practice: the evolving role of hypertonic saline. Neurosurgery 2005, 57:207-215.
91. Qureshi AI, Suarez JI, Bhardwaj A, et al.: Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: effect on intracranial pressure and lateral displacement of the brain. Crit Care Med 1998, 26:440-446.
92. Suarez JI, Qureshi AI, Bhardwaj A, et al.: Treatment of refractory intracranial hypertension with 23.4% saline. Crit Care Med 1998, 26:1118-1122.
93. Fernandes HM, Gregson B, Siddique S, Mendelow AD: Surgery in intracerebral hemorrhage. The uncertainty continues. Stroke 2000, 31:2511-2516.
94. Mendelow AD, Gregson BA, Fernandes HM, et al.: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387-397.
95. Nishihara T, Nagata K, Tanaka S, et al.: Newly developed endoscopic instruments for the removal of intracerebral hematoma. Neurocrit Care 2005, 2:67-74.
96. Vespa P, McArthur D, Miller C, et al.: Frameless stereotactic aspiration and thrombolysis of deep intracerebral hemorrhage is associated with reduction of hemorrhage volume and neurologic improvement. Neurocrit Care 2005, 2:274-281.
97. Teernstra OP, Evers SM, Lodder J, et al.: Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA). Stroke 2003, 34:968-974.
98. Murthy JM, Chowdary GV, Murthy TV, et al.: Decompressive craniectomy with clot evacuation in large hemispheric hypertensive intracerebral hemorrhage. Neurocrit Care 2005, 2:258-262.